Takeshi Shimamura
Takeshi Shimamura
Associate Professor, Department of Surgery, University of Illinois at Chicago
Verified email at
Cited by
Cited by
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D Li, L Ambrogio, T Shimamura, S Kubo, M Takahashi, LR Chirieac, ...
Oncogene 27 (34), 4702-4711, 2008
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung TumorsImmune Escape of EGFR-Mutant Tumors through PD-1
EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ...
Cancer discovery 3 (12), 1355-1363, 2013
LKB1 modulates lung cancer differentiation and metastasis
H Ji, MR Ramsey, DN Hayes, C Fan, K McNamara, P Kozlowski, C Torrice, ...
Nature 448 (7155), 807-810, 2007
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ...
Cancer research 67 (24), 11924-11932, 2007
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsResistance Mechanisms in ALK Kinase Inhibitors
T Sasaki, J Koivunen, A Ogino, M Yanagita, S Nikiforow, W Zheng, ...
Cancer research 71 (18), 6051-6060, 2011
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
H Ji, D Li, L Chen, T Shimamura, S Kobayashi, K McNamara, U Mahmood, ...
Cancer cell 9 (6), 485-495, 2006
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Z Chen, K Cheng, Z Walton, Y Wang, H Ebi, T Shimamura, Y Liu, ...
Nature 483 (7391), 613-617, 2012
STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor MicroenvironmentImmunosuppressive …
S Koyama, EA Akbay, YY Li, AR Aref, F Skoulidis, GS Herter-Sprie, ...
Cancer research 76 (5), 999-1008, 2016
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor
CL Christensen, N Kwiatkowski, BJ Abraham, J Carretero, F Al-Shahrour, ...
Cancer cell 26 (6), 909-922, 2014
Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
ML Sos, K Michel, T Zander, J Weiss, P Frommolt, M Peifer, D Li, R Ullrich, ...
The Journal of clinical investigation 119 (6), 1727-1740, 2009
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
H Ji, X Zhao, Y Yuza, T Shimamura, D Li, A Protopopov, BL Jung, ...
Proceedings of the National Academy of Sciences 103 (20), 7817-7822, 2006
Somatic LKB1 mutations promote cervical cancer progression
SN Wingo, TD Gallardo, EA Akbay, MC Liang, CM Contreras, T Boren, ...
PloS one 4 (4), e5137, 2009
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase InhibitorsERK Signaling and EGFR Resistance
D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero, ...
Cancer discovery 2 (10), 934-947, 2012
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins
T Shimamura, AM Lowell, JA Engelman, GI Shapiro
Cancer research 65 (14), 6401-6408, 2005
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy
D Li, T Shimamura, H Ji, L Chen, HJ Haringsma, K McNamara, MC Liang, ...
Cancer cell 12 (1), 81-93, 2007
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors
J Carretero, T Shimamura, K Rikova, AL Jackson, MD Wilkerson, ...
Cancer cell 17 (6), 547-559, 2010
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene
Z Chen, T Sasaki, X Tan, J Carretero, T Shimamura, D Li, C Xu, Y Wang, ...
Cancer research 70 (23), 9827-9836, 2010
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R PathwayResistance to Irreversible EGFR Inhibitors
AB Cortot, CE Repellin, T Shimamura, M Capelletti, K Zejnullahu, D Ercan, ...
Cancer research 73 (2), 834-843, 2013
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
SA Perera, D Li, T Shimamura, MG Raso, H Ji, L Chen, CL Borgman, ...
Proceedings of the National Academy of Sciences 106 (2), 474-479, 2009
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung CancerBET Bromodomain Inhibitor in Mutant KRAS NSCLC
T Shimamura, Z Chen, M Soucheray, J Carretero, E Kikuchi, JH Tchaicha, ...
Clinical cancer research 19 (22), 6183-6192, 2013
The system can't perform the operation now. Try again later.
Articles 1–20